ubmslateCN-logo-ubm

CN Mobile Logo

Topics:

Sarcoma

Some Sarcomas May Require Long-Term Follow-Up

Although rare, long-term recurrence of soft-tissue sarcoma is possible, and patients with retroperitoneal, very large sarcomas, or high-grade disease should undergo long-term follow-up to detect late disease recurrence.

Sarcoma

A retrospective study was used to develop nomograms predictive of both metastasis-free and overall survival for patients with nonmetastatic osteosarcoma.

In a phase I study, gemcitabine given concurrently with fixed-dose EBRT showed promising results following surgery in patients with high-risk soft-tissue sarcoma.

Early trial results found that the addition of olaratumab to doxorubicin dramatically improves survival in patients with advanced soft-tissue sarcoma.

In this video, Dr. Tap discusses a randomized phase Ib/II trial that found that adding olaratumab to doxorubicin dramatically improved survival in patients with advanced soft-tissue sarcoma.

Treating advanced sarcoma with the chemotherapy agent eribulin improves overall survival compared with treatment with standard therapy with dacarbazine.

Trabectedin failed to improve progression-free survival outcomes compared to doxorubicin as first-line therapy for advanced/metastatic soft-tissue sarcoma.

T cells that express a HER2-specific chimeric antigen receptor showed promise as a treatment for HER-2 positive sarcoma in a small phase I/II trial.

Pages

Subscribe to Sarcoma on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.